Story perspectives

FDA Approves Updated 2026–2027 COVID Vaccines for JN.1 XFG

9/1/2026

Summary

Story summary

The U.S. Food and Drug Administration approved updated COVID-19 vaccines for the 2026-2027 season.
Moderna, Pfizer, and Novavax/Sanofi received approval for age-specific updated vaccines.
All updated shots target the JN.1-lineage XFG variant, which drives about 40% of U.S. cases.
CDC reports test positivity near 5% for the week ending Aug. 15, the highest since February.
Health experts urge vaccination now for high-risk groups, including 65+, immunocompromised, pregnant people, and infants 6-23 months.

1 of 1

Story summary

The U.S. Food and Drug Administration approved updated COVID-19 vaccines for the 2026-2027 season.
Moderna, Pfizer, and Novavax/Sanofi received approval for age-specific updated vaccines.
All updated shots target the JN.1-lineage XFG variant, which drives about 40% of U.S. cases.
CDC reports test positivity near 5% for the week ending Aug. 15, the highest since February.
Health experts urge vaccination now for high-risk groups, including 65+, immunocompromised, pregnant people, and infants 6-23 months.